Newcells Biotech Limited, a team of internationally recognised experts in the building and application of complex models of human tissues for drug discovery, was awarded £1m to deliver their…
Read update 5th May, 2023About the conference: ARVO The ARVO conference took place in the New Orleans Ernest N. Morial Convention Center. With over 10 000 attendees, the venue was absolutely huge. If you…
Read update 28th April, 2023Why develop an RPE model? Retinal pigment epithelium (RPE) cells play a vital role in the retina by forming the outer blood-retinal barrier and maintaining photoreceptor and visual…
Read update 20th April, 2023One the fastest growing approaches to treat cancer is the use of antibody drug conjugates (ADCs). Since the approval of the first antibody drug conjugate in 2000,…
Read update 15th June, 2022Adeno Associated Virus (AAV) vectors have emerged as the most successful retinal gene therapy vectors following the FDA approval of Luxturna in 2017. This new gene therapy product is…
Read update 28th April, 2022Retinal diseases have been at the forefront of gene and cell therapy over the last 30 years with conditions such as macular degeneration and Stargardt disease likely to be…
Read updateNewcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes,…
Read update 12th July, 2024A Unique Exhibition-Poster Integration One striking feature of JSOT is how they seamlessly integrate exhibitions with poster sessions. Exhibitors and poster presenters are…
Read update 8th July, 2024Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes,…
Read update 28th June, 2024How does Newcells works with their clients? Listen to our CEO, Dr Mike Nicholds explaining. Webinar on demand: Moving compounds to IND using predictive retinal models. Our panel of experts…
Read update 11th June, 2024Dr Valeria Chichagova appointed as Director of Technology, Dr Colin Brown as Chief Scientific Officer, and Professor Lyle Armstrong as Scientific Advisor New US commercial appointments also announced…
Read update 6th March, 2024The Newcastle-based company has secured funding from existing investors including the North East Venture Fund, supported by the European Regional Development Fund and managed by Mercia Ventures, Mercia’s own funds…
Read update